Patents by Inventor Antonio SEGURA CARRETERO

Antonio SEGURA CARRETERO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias
    Patent number: 11951090
    Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: April 9, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE PARIS, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, UNIVERSIDAD DE GRANADA
    Inventors: Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED CHONDRODYSPLASIAS
    Publication number: 20230414561
    Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
    Type: Application
    Filed: September 8, 2023
    Publication date: December 28, 2023
    Inventors: Laurence LEGEAI-MALLET, Antonio SEGURA CARRETERO, Maria De La Luz CADIZ GURREA
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FGFR3-RELATED CHONDRODYSPLASIAS
    Publication number: 20210052546
    Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 25, 2021
    Inventors: Laurence LEGEAI-MALLET, Antonio SEGURA CARRETERO, Maria De La Luz CADIZ GURREA